Antifibrotic effects of a novel pirfenidone derivative in vitro and in vivo

被引：16
|
作者：
Ma, Zhen [1 ]
Zhao, Cungang [1 ]
Chen, Qi [1 ]
Yu, Chenhuan [2 ]
Zhang, Huanhuan [2 ]
Zhang, Zhimin [1 ]
Huang, Wenhai [1 ]
Shen, Zhengrong [1 ]
机构：
[1] Zhejiang Acad Med Sci, Inst Mat Med, 182 Tianmushan Rd, Hangzhou 310013, Zhejiang, Peoples R China
[2] Zhejiang Acad Med Sci, Lab Anim Ctr, Hangzhou 310013, Zhejiang, Peoples R China
来源：
PULMONARY PHARMACOLOGY & THERAPEUTICS | 2018年 / 53卷
关键词：
Pirfenidone derivative; Antifibrotic effect; Mechanism; TGF-beta; 1; Smad3; p38; EPITHELIAL-MESENCHYMAL TRANSITION; PULMONARY-FIBROSIS; PATHOGENESIS; BLEOMYCIN; PATHWAYS; DESIGN; KINASE; MAPK;
D O I：
10.1016/j.pupt.2018.10.006
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Background: Idiopathic pulmonary fibrosis is a lethal fibrosing interstitial pneumonia characterized by progressive worsening of dyspnea and lung function with poor prognosis. Since pirfenidone was approved for IPF treatment, the search for more effective candidates has been greatly intensified. Methods: In this study, the antifibrotic effects and mechanisms of compound PBD-617, the ideal candidate discovered in our previous work, were investigated on transforming growth factor-beta 1 (TGF-beta 1)-induced human embryonic lung fibroblasts (HELF) and on bleomycin (BLM)-induced pulmonary fibrotic rats. Results: Oral administration with PBD-617 decreased the levels of collagen I, collagen III and matrix metalloproteinase 7, and inhibited the protein expression of alpha-smooth muscle actin in BLM-induced pulmonary fibrosis rats. Furthermore, PBD-617 suppressed the expression of TGF-beta 1, phosphorylated Smad3, phosphorylated p38 and activator protein 1 on TGF-beta 1-induced HELF, while the regulation could be rescued by using p38 agonist p79350. Conclusion: PBD-617 not only inhibited TGF-beta 1-induced HELF proliferation, but also attenuated BLM-induced pulmonary fibrosis in rats, with efficacy to some extent higher than that of pirfenidone at the same effective dosage. PBD-617 attenuated pulmonary fibrosis effectively by suppressing activation of TGF-beta 1/Smad3 and p38 signaling pathways.
引用
收藏
页码：100 / 106
页数：7
相关论文
共 50 条
  • [41] A Novel Triazole Derivative Drug Presenting In Vitro and In Vivo Anticancer Properties
    Imbroisi Filho, Ricardo
    Gonzaga, Daniel T. G.
    Demaria, Thaina M.
    Leandro, Joao G. B.
    Costa, Dora C. S.
    Ferreira, Vitor F.
    Sola-Penna, Mauro
    da Silva, Fernando de C.
    Zancan, Patricia
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2018, 18 (17) : 1483 - 1493
  • [42] In vitro and in vivo antitumor activity of a novel chlorin derivative for photodynamic therapy
    Zhang, C. Y.
    Zhang, L. J.
    Li, J. W.
    Li, J. H.
    Wu, Z. M.
    Zhang, L. X.
    Chen, N.
    Yan, Y. J.
    Chen, Z. L.
    NEOPLASMA, 2016, 63 (01) : 37 - 43
  • [43] In Vitro and In Vivo Antitumor Activity of a Novel Semisynthetic Derivative of Cucurbitacin B
    Silva, Izabella T.
    Carvalho, Annelise
    Lang, Karen L.
    Dudek, Sabine E.
    Masemann, Doerthe
    Duran, Fernando J.
    Caro, Miguel S. B.
    Rapp, Ulf R.
    Wixler, Viktor
    Schenkel, Eloir P.
    Simoes, Claudia M. O.
    Ludwig, Stephan
    PLOS ONE, 2015, 10 (02):
  • [44] In Vitro and In Vivo Antifibrotic Effects of Fraxetin on Renal Interstitial Fibrosis via the ERK Signaling Pathway
    Hsieh, Yi-Hsien
    Hung, Tung-Wei
    Chen, Yong-Syuan
    Huang, Yi-Ning
    Chiou, Hui-Ling
    Lee, Chu-Che
    Tsai, Jen-Pi
    TOXINS, 2021, 13 (07)
  • [45] Pirfenidone as a potential antifibrotic injectable for Dupuytren's disease
    Panigrahi, Suchitra
    Barry, Amanda
    Multner, Scott
    Kasting, Gerald B.
    Figueroa, Julio A. Landero
    Satish, Latha
    Kumari, Harshita
    PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2022, 27 (02) : 242 - 250
  • [46] Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGFβ-induced lung fibrosis
    Afshin Ebrahimpour
    Manisha Ahir
    Min Wang
    Anil G. Jegga
    Mark D. Bonnen
    N. Tony Eissa
    Sydney B. Montesi
    Ganesh Raghu
    Yohannes T. Ghebre
    Scientific Reports, 12
  • [47] Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGFβ-induced lung fibrosis
    Ebrahimpour, Afshin
    Ahir, Manisha
    Wang, Min
    Jegga, Anil G.
    Bonnen, Mark D.
    Eissa, N. Tony
    Montesi, Sydney B.
    Raghu, Ganesh
    Ghebre, Yohannes T.
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [48] Synthesis and In vivo Antifibrotic Activity of Novel Leflunomide Analogues
    Hamdi, Abdelrahman
    Said, Eman
    Farahat, Abdelbasset A.
    El-Bialy, Serry A. A.
    Massoud, Mohammed A. M.
    LETTERS IN DRUG DESIGN & DISCOVERY, 2016, 13 (09) : 912 - 920
  • [49] Novel peptides with neuroprotective effects in vitro and in vivo
    Bardutzky, J
    Siddiq, A
    Ratan, RR
    Shashoua, VE
    Gannon, KS
    Kates, SA
    Fisher, M
    STROKE, 2005, 36 (02) : 514 - 514
  • [50] Synthesis and biological evaluation of the pirfenidone derivatives as antifibrotic agents
    Ma, Zhen
    Pan, Youlu
    Huang, Wenhai
    Yang, Yewei
    Wang, Zunyuan
    Li, Qin
    Zhao, Yin
    Zhang, Xinyue
    Shen, Zhengrong
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (01) : 220 - 223
12345